曲美他嗪治疗扩张型心肌病的Meta分析

目的评价联合应用曲美他嗪治疗扩张性心肌病的疗效及安全性。方法计算机检索Cochrane Library、PubMed、BioMed Central、中国学术期刊全文数据库、维普数据库、万方数据库,收集曲美他嗪治疗扩张性心肌病的随机对照试验,按纳入和排除标准由2名评价者独立选择文献,提取资料,交叉核对并进行方法学质量评估,使用RevMan5.0软件进行Meta分析。结果共纳入35项研究,2267例患者。Meta分析结果显示:与常规治疗比较,联合应用曲美他嗪明显增加左室射血分数(WMD=5.89,95%CI:5.80~5.99,P<0.01),降低脑钠钛水平(WMD=-82.66,95%CI:-97.40^-67.93,P<0.01),增加心搏出量(WMD=0.65,95%CI:0.52~0.77,P<0.01)。结论曲美他嗪可改善患者心功能。

A Meta-analysis on curative effect and safety of trimetazidine in the treatment of dilated cardiomyopathy

Objective To review the curative effect and safety of trimetazidine in the treatment of dilated cardiomyopathy.Methods The databases of Cochrane Controlled Trials Register/CENTRAL,Pubmed,Biomed Central,CJFD,VIP Database and WangFang Database were retrieved with computers for collecting randomized controlled trials(RCT) about the treatment of dilated cardiomyopathy with trimetazidine.The RCT were selected by two researchers independently according to inclusion and exclusion criterions and materials were extracted,checked crossly and given methodological quality evalution.The Meta-analysis was conducted by using RevMan5.0 software.Results There were totally 35 RCTs enclosed,and the results of Meta-analysis showed that trimetazidine increased significantly LVEF(WMD=5.89,5%CI:5.80-5.99,P<0.01),decreased BNP level (WMD=-82.66,95%CI:-97.40--67.93,P<0.01),increased CO (WMD=0.65,95%CI:0.52-0.77,P<0.01).Conclusion The existing evidences indicate that trimetazidine can improve the heart functional.